Biocon Biologics' biosimilar human insulin gets backing from EMA expert panel

The EMA's Committee for Medicinal Products for Human Use (CHMP) opinion will be considered by the European Commission. "The European Commission decision on the approval is expected later this year," Biocon Biologics said. Once approved by EMA, the company said it commercialise Inpremzia in the EU by a leading global medical products company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H3if1Cb
via IFTTT